Cargando…

Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated

Low frequency of durable responses in patients treated with immune checkpoint inhibitors (ICIs) demands for taking complementary strategies in order to boost immune responses against cancer. Transforming growth factor‐β (TGF‐β) is a multi‐tasking cytokine that is frequently expressed in tumours and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mortezaee, Keywan, Majidpoor, Jamal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889687/ https://www.ncbi.nlm.nih.gov/pubmed/36625080 http://dx.doi.org/10.1111/jcmm.17666

Ejemplares similares

Anti-PD-(L)1 therapy of non-small cell lung cancer–A summary of clinical trials and current progresses
por: Mortezaee, Keywan, et al.
Publicado: (2023)

Checkpoint inhibitor/interleukin‐based combination therapy of cancer
por: Mortezaee, Keywan, et al.
Publicado: (2022)

Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
por: Majidpoor, Jamal, et al.
Publicado: (2022)

(Im)maturity in Tumor Ecosystem
por: Mortezaee, Keywan, et al.
Publicado: (2022)

CD8(+) T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives
por: Mortezaee, Keywan, et al.
Publicado: (2022)

Cellular immune states in SARS-CoV-2-induced disease
por: Mortezaee, Keywan, et al.
Publicado: (2022)

Extracellular vesicle–based drug delivery in cancer immunotherapy
por: Najafi, Sajad, et al.
Publicado: (2023)

Transforming growth factor-β in tumour development
por: Trelford, Charles B., et al.
Publicado: (2022)

CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
por: Seitz, Stefanie, et al.
Publicado: (2022)

Combined Effect of Retinoic Acid and Basic Fibroblast Growth Factor on Maturation of Mouse Oocyte and Subsequent Fertilization and Development
por: Abouzaripour, Morteza, et al.
Publicado: (2018)

Tumour‐derived transforming growth factor‐β signalling contributes to fibrosis in patients with cancer cachexia
por: Lima, Joanna D.C.C., et al.
Publicado: (2019)

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
por: Chen, Jiming, et al.
Publicado: (2022)

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
por: Lau, Janet, et al.
Publicado: (2017)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
por: Yi, Ming, et al.
Publicado: (2022)

Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signalling
por: Weidenaar, A C, et al.
Publicado: (2011)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

Transforming Growth Factor β Signaling Overcomes Dasatinib Resistance in Lung Cancer
por: Gordian, Edna, et al.
Publicado: (2014)

Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy
por: Sheen, Yhun Yhong, et al.
Publicado: (2013)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Genomic Instability and Carcinogenesis of Heavy Charged Particles Radiation: Clinical and Environmental Implications
por: Mortezaee, Keywan, et al.
Publicado: (2019)

Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer
por: Kretzschmar, Marcus
Publicado: (2000)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
por: Abdin, Shifaa M., et al.
Publicado: (2018)

Znf45l affects primitive hematopoiesis by regulating transforming growth factor-β signaling
por: Chen, Huijuan, et al.
Publicado: (2014)

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Expression Patterns for TETs, LGR5 and BMI1 in Cancer Stem-like Cells Isolated from Human Colon Cancer
por: Atlasy, Nader, et al.
Publicado: (2019)

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer
por: Alburquerque-Bejar, Juan J., et al.
Publicado: (2023)

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
por: Mariathasan, Sanjeev, et al.
Publicado: (2018)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
por: Passariello, Margherita, et al.
Publicado: (2019)

Transforming growth factor-β signaling in systemic sclerosis
por: Ayers, Nolan B., et al.
Publicado: (2018)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
por: Puri, Sonam, et al.
Publicado: (2020)

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
por: Johnson, Douglas B., et al.
Publicado: (2016)

Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer
por: Cheng, Bo, et al.
Publicado: (2022)

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance
por: Zhang, Yan, et al.
Publicado: (2017)

Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers
por: Lv, Xiaoqun, et al.
Publicado: (2021)

Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
por: Chan, Max Kam-Kwan, et al.
Publicado: (2023)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
por: Shah, Shalin, et al.
Publicado: (2017)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
por: Mishra, Surbhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b533nuq78avcvrof9b1n3gt0cj